Coronavirus Disease 2019 Clinical Trial
Official title:
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers]
The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injections in subjects experiencing prolonged symptoms (> 12 weeks) of COVID-19.
This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with prolonged symptoms caused by Coronavirus Disease 2019 (COVID-19). Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection. The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period. Total study duration is 91 days. The study will be conducted at up to 5 centers in the United States and planned number of subjects are 50 subjects. Visit schedule: Visit 1 - Screening assessment Visit 2 - baseline, first dose Visit 3 - no dose, baseline+3 days Visit 4 - second dose, baseline + 7 days Visit 5 - no dose, safety assessment/con med, baseline +10 days Visit 6 - third dose, baselines + 14 days Visit 7 - no dose, safety assessments, baseline + 17 days Visit 8 - fourth dose, baseline +21 days Visit 9 - no dose, safety assessment, baseline + 24 days Visit 10 - fifth dose, baseline + 28 days Visit 11 - no dose, safety assessment, baseline + 31 days Visit 12 - sixth dose, baseline + 35 days Visit 13 - no dose, safety assessment, baseline + 38 days Visit 14 - seventh dose, baseline + 42 days Visit 15 - no dose, safety assessment, baseline + 45 days Visit 16 - eighth and final dose, baseline + 49 days Visit 17 - End of treatment, baseline + 56 days ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05091411 -
Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)
|
Phase 3 | |
| Completed |
NCT05107375 -
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
|
Phase 3 | |
| Active, not recruiting |
NCT05128643 -
Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell)
|
Phase 3 | |
| Completed |
NCT04988217 -
Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)
|
Phase 1/Phase 2 | |
| Completed |
NCT04579393 -
Fostamatinib for Hospitalized Adults With COVID-19
|
Phase 2 | |
| Withdrawn |
NCT04390217 -
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
|
Phase 2 | |
| Recruiting |
NCT05047783 -
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
|
Phase 2 | |
| Completed |
NCT04646044 -
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
|
Phase 1 | |
| Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
| Recruiting |
NCT05092568 -
Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
|
||
| Completed |
NCT05364268 -
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
|
||
| Completed |
NCT06189040 -
Immunogenicity After COVID-19 Vaccines in Adapted Schedules
|
Phase 4 | |
| Recruiting |
NCT04401436 -
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
|
||
| Not yet recruiting |
NCT04395742 -
1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study
|
||
| Recruiting |
NCT04388631 -
Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.
|
||
| Completed |
NCT05501288 -
Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019
|
N/A | |
| Active, not recruiting |
NCT05216471 -
Identify Coronavirus Disease by Chest X-ray
|
||
| Terminated |
NCT04672564 -
Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
|
Phase 3 | |
| Completed |
NCT04967781 -
Autoimmunity Contributes to the Severe Progression of COVID-19
|
||
| Completed |
NCT04497194 -
Registry of COVID-19 Patients at AOUI Verona
|